BioMarin Pharmaceutical | Pasivo Circulante



Current Liabilities Cambio Fecha
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
Amgen USD 23.1B 2.79B 2024-12
Bayer EUR 28.95B 3.9B 2024-12
Biogen USD 5.53B 103.8M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Gilead Sciences USD 12B 279M 2024-12
Incyte USD 1.89B 244.96M 2025-03
Insmed USD 297.53M 38.34M 2024-12
Ionis Pharmaceuticals USD 250.29M 59.02M 2025-03
Moderna USD 1.6B 602M 2025-03
Neurocrine Biosciences USD 507.7M 78M 2024-12
PTC Therapeutics USD 580.98M 29.73M 2024-12
Regeneron Pharmaceuticals USD 3.57B 2.13B 2025-03
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 29.16B 865M 2024-12
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
United Therapeutics USD 721.5M 16.6M 2025-03
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



BioMarin Pharmaceutical Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.